中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2011年
23期
3203-3204
,共2页
心力衰竭,充血性%心功能%曲美他嗪
心力衰竭,充血性%心功能%麯美他嗪
심력쇠갈,충혈성%심공능%곡미타진
Heart failure,congestive%Heart function%Trimetazidine
目的 观察曲美他嗪(TMZ)治疗慢性心力衰竭(CHF)的临床疗效.方法 70例CHF患者随机分为对照组和治疗组各35例,对照组给予抗心力衰竭常规治疗,治疗组在对照组的基础上加用TMZ,20 mg/次,3次/d.8周后观察比较两组心功能改善情况.结果 治疗组治疗前左室射血分数(LVEF)(38.0±2.4)％,治疗后LVEF(48.0±2.3)％；对照组治疗前LVEF(38.2±2.2)％,治疗后LVEF(42.0±2.5)％；两组LVEF治疗前后差异均有统计学意义(t=6.9419、2.8482,均P＜0.05)；治疗组治疗后较对照组改善更明显(t =4.3147,P＜0.05).对照组再住院10例(28.5％),治疗组再住院3例(8.5％),两组再住院率差异有统计学意义(x2=4.629,P＜0.05).两组均未见死亡病例,均未发生严重不良反应.结论 在常规抗心衰治疗的基础上加用TMZ可显著改善慢性心力衰竭患者的心功能,降低再住院率.
目的 觀察麯美他嗪(TMZ)治療慢性心力衰竭(CHF)的臨床療效.方法 70例CHF患者隨機分為對照組和治療組各35例,對照組給予抗心力衰竭常規治療,治療組在對照組的基礎上加用TMZ,20 mg/次,3次/d.8週後觀察比較兩組心功能改善情況.結果 治療組治療前左室射血分數(LVEF)(38.0±2.4)％,治療後LVEF(48.0±2.3)％；對照組治療前LVEF(38.2±2.2)％,治療後LVEF(42.0±2.5)％；兩組LVEF治療前後差異均有統計學意義(t=6.9419、2.8482,均P＜0.05)；治療組治療後較對照組改善更明顯(t =4.3147,P＜0.05).對照組再住院10例(28.5％),治療組再住院3例(8.5％),兩組再住院率差異有統計學意義(x2=4.629,P＜0.05).兩組均未見死亡病例,均未髮生嚴重不良反應.結論 在常規抗心衰治療的基礎上加用TMZ可顯著改善慢性心力衰竭患者的心功能,降低再住院率.
목적 관찰곡미타진(TMZ)치료만성심력쇠갈(CHF)적림상료효.방법 70례CHF환자수궤분위대조조화치료조각35례,대조조급여항심력쇠갈상규치료,치료조재대조조적기출상가용TMZ,20 mg/차,3차/d.8주후관찰비교량조심공능개선정황.결과 치료조치료전좌실사혈분수(LVEF)(38.0±2.4)％,치료후LVEF(48.0±2.3)％；대조조치료전LVEF(38.2±2.2)％,치료후LVEF(42.0±2.5)％；량조LVEF치료전후차이균유통계학의의(t=6.9419、2.8482,균P＜0.05)；치료조치료후교대조조개선경명현(t =4.3147,P＜0.05).대조조재주원10례(28.5％),치료조재주원3례(8.5％),량조재주원솔차이유통계학의의(x2=4.629,P＜0.05).량조균미견사망병례,균미발생엄중불량반응.결론 재상규항심쇠치료적기출상가용TMZ가현저개선만성심력쇠갈환자적심공능,강저재주원솔.
Objective To explore the clinical effect of chlorpromazine(TMZ)in treatment of chronic heart failure(CHF).Methods 70 patients with CHF were randomly divided into control group and treatment group 35 cases in each gronp,control group was given conventional treatment,treatment group on the basis of additional application TMZ,20mg/times,3 times/d.8 weeks after the observation and comparison of two groups of cardiac function in improving the situation.Results Treatment group before the treatment of LVEF(38.0 ± 2.4)％ After treatment,LVEF(48.0 ±2.3)％ ;control group before treatment LVEF(38.2 ±2.2)％ after treatment,LVEF(42.0 t2.5)％ ;Twosets of treatment LVEFdifference statistically significant(t =6.9419,2.8482,allP ＜ 0.05); Treatment group compared with control groups after treatment improve even more obvious(t =4.3147,P ＜0.05)o Control groups and then hospitalized 10 cases(28.5％),the treatment group hospitalization 3 cases(8.5％),both groups rate difference statistically significant(x2 =4.629,P ＜0.05).Both groups were no deaths,no serious adverse effects.Conclusion General against heart failure therapy on the basis of the combined with TMZ could significantly improve the cardiac function of patients with chronic heart failure,reducing hospitalization rates.
